drugset
drugset / Trial / NCT00189813

A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)

NCT00189813 ↗

Phase 2 Completed 691 enrolled Astellas Pharma Inc Astellas Pharma Europe B.V. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will examine the efficacy, safety and tolerability of different oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.

Timeline

Start
2005-03
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramosetron Small molecule — Oral

Indications

irritable bowel syndrome